Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio

Rhea-AI Summary

Nutriband (NASDAQ: NTRB / NTRBW) signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5.0 million. Shareholders will retain a 10% stake in EarthVision Bio after the transaction. The expected closing date is Dec 31, 2025. Nutriband said it will use sale proceeds to fund continued development of AVERSA Fentanyl, described as a potential abuse‑deterrent transdermal fentanyl patch. The company disclosed projected potential US annual sales for AVERSA Fentanyl of $80M–$200M.

EarthVision Bio is described as commercializing sustainable products developed by Dr. Gordon Moore and Dr. Hans Franke; Nutriband will no longer hold majority control of Pocono Pharmaceutical after closing.

Positive

• Sale of 90% of Pocono Pharmaceutical for $5.0M
• Shareholders retain a 10% ownership stake in EarthVision Bio
• Proceeds earmarked to fund development of AVERSA Fentanyl
• Projected US sales for AVERSA: $80M–$200M (company disclosure)

Negative

• Nutriband will relinquish majority control (90%) of Pocono Pharmaceutical
• Sale proceeds of $5.0M are the only disclosed funding source for AVERSA development

Key Figures

Pocono stake sale $5M Sale of 90% interest in Pocono Pharmaceutical to EarthVision Bio

Interest sold 90% Equity interest in Pocono Pharmaceutical being sold to EarthVision Bio

Retained stake 10% Nutriband shareholders’ post-transaction shareholding in EarthVision Bio

AVERSA peak sales $80M–$200M Projected annual U.S. sales potential for AVERSA Fentanyl

Quarter revenue $346,058 Revenue for quarter ended Oct 31, 2025, from Pocono segment

Nine‑month revenue $1.64M Nine-month revenue vs $1.50M prior year, Pocono segment

Nine‑month net loss $7.26M Nine-month net loss driven by SG&A and AVERSA R&D

Cash balance $5.31M Cash as of Oct 31, 2025, before Pocono sale proceeds

Market Reality Check

$1.61 Last Close

Volume Volume 12,246 is below the 20-day average of 19,579 (relative volume 0.63). low

Technical Shares at $4.80 were trading below the $6.52 200-day moving average and well under the $11.78 52-week high.

Peers on Argus

Peers showed mixed moves, with CVM up 0.86% and STRO up 7.08%, while OKYO, QNCX, and XBIT declined between 0.40% and 2.93%, suggesting stock-specific rather than sector-driven dynamics for NTRB.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 18	Technology LOI	Positive	+3.0%	Non-binding LOI with Qvanta to explore advanced technology for R&D support.
Dec 18	Program positioning	Positive	+3.0%	Highlighted AVERSA Fentanyl and differentiated prescription from illicit fentanyl risks.
Nov 24	Conference presentation	Positive	-2.1%	Announced NobleCon21 conference presentation and webcast access for investors.
Oct 28	FDA meeting update	Positive	+10.4%	Reported FDA guidance and 505(b)(2) NDA pathway for AVERSA Fentanyl.
Oct 27	Leadership change	Positive	-1.7%	Co-founder Gareth Sheridan returned as CEO to drive NDA plans.

Pattern Detected

Recent AVERSA Fentanyl and strategic updates generally saw modest positive price reactions, with occasional divergences on conference participation and leadership changes.

Recent Company History

Over the last few months, Nutriband has focused communications on its AVERSA Fentanyl program and corporate positioning. On Oct 27, 2025, the co-founder returned as CEO to steer toward an NDA filing in 2026. An FDA meeting update on Oct 28, 2025 produced the strongest move at +10.38%. Subsequent conference participation and technology collaboration news in November and December saw smaller, mixed reactions. Today’s divestiture of Pocono Pharmaceutical to fund AVERSA development fits this ongoing strategic focus.

Market Pulse Summary

This announcement highlights Nutriband’s decision to sell 90% of Pocono Pharmaceutical for $5M and redirect resources toward AVERSA Fentanyl, which carries projected U.S. sales potential of $80M–$200M. Recent filings showed nine‑month revenue of $1.64M from Pocono and a net loss of $7.26M, so redeploying capital is significant. Investors may watch closing by Dec 31, 2025, AVERSA regulatory milestones, and future funding disclosures.

Key Terms

abuse-deterrent medical

"world's first and only abuse-deterrent opioid patch designed to deter the abuse"

A product described as abuse-deterrent is designed to make intentional misuse—such as crushing, dissolving or injecting—harder or less rewarding, often through physical barriers, additives that make tampering difficult, or properties that cause unpleasant effects if manipulated. For investors, such features can change a drug’s regulatory path, market acceptance, insurance coverage and legal risk, much like adding a safety lock can alter a product’s appeal, liability and sales potential.

opioid medical

"world's first and only abuse-deterrent opioid patch designed to deter the abuse"

An opioid is a type of drug that reduces pain by binding to receptors in the nervous system; it includes prescription painkillers and some illegal substances. Investors care because opioids carry medical benefit but also risks—addiction, heavy regulation, litigation and changing prescribing practices—that can affect sales, legal costs, reputations and future product approvals, much like how a product recall or safety scandal can quickly change a company’s value.

transdermal medical

"reduce the risk of accidental exposure of transdermal fentanyl patches"

Transdermal describes a method of delivering a drug through the skin so the active ingredient is absorbed into the bloodstream, commonly via a patch, gel or cream. For investors, transdermal delivery affects a product’s convenience, steady dosing, patent and regulatory profile, manufacturing needs and market appeal—similar to a slow-release battery that makes a device easier to use and last longer, which can influence sales potential and risk.

fentanyl medical

"AVERSA Fentanyl which has the potential to be the world's first"

Fentanyl is a very powerful synthetic opioid used medically to treat severe pain and, in illicit form, can be deadly at much smaller doses than other painkillers. Investors pay attention because its medical use, strict regulation, growing illegal market and related legal or public‑health actions can affect drugmakers, hospitals, emergency services and broader liability or demand for treatments—similar to how a single safety issue can reshape an entire industry.

AI-generated analysis. Not financial advice.

Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe

Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition

The expected closing date for the transaction is Dec 31, 2025.

ORLANDO, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that it has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio.

Earthvision Bio has developed and are commercializing a new category of sustainable products created by Dr. Gordon Moore, the founder of Intel (NASDAQ: INTC), and Dr. Hans Franke, who was board chairman for Chevron Europe. The Company has developed a sustainable way to replace plastic, molded fiber, wood, and paper products with Earth-friendly alternatives.

Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition.

Nutriband inc. will use the proceeds from the sale of Pocono Pharma towards its continued development of AVERSA Fentanyl which has the potential to be the world's first and only abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach annual US sales of $80 million to $200 million.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

Earthvision Bio
Tina Hoefer
Phone: 213-531-9995
Email: Tina@earthvisionbio.com

SOURCE: Nutriband Inc.

FAQ

What did Nutriband (NTRB) agree to sell on Dec 29, 2025?

Nutriband agreed to sell a 90% interest in Pocono Pharmaceutical to EarthVision Bio for $5.0M.

When is the Nutriband Pocono Pharmaceutical sale expected to close?

The transaction is expected to close on Dec 31, 2025.

How much ownership will Nutriband shareholders keep in EarthVision Bio after the deal?

Nutriband shareholders will retain a 10% stake in EarthVision Bio following the acquisition.

What will Nutriband use the $5M sale proceeds for?

Proceeds will be used to continue development of AVERSA Fentanyl, the company's abuse‑deterrent patch candidate.

What sales outlook did Nutriband disclose for AVERSA Fentanyl?

The company disclosed potential annual US sales of $80 million to $200 million for AVERSA Fentanyl.

Who is EarthVision Bio and what products do they develop?

EarthVision Bio is described as commercializing sustainable alternatives to plastic, molded fiber, wood, and paper developed by Dr. Gordon Moore and Dr. Hans Franke.